Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Griseofulvin, Microsize

FDA-approved product (tablet, oral), marketed as Grifulvin V, Grisactin, Fulvicin-U/F and 10 more.

Registered studies
9
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Griseofulvin, Microsize
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Candidiasis
  • Infection
  • Tinea
  • Tinea pedis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics; Antifungals for systemic use
FDA pharmacologic class
Tubulin Inhibiting Agent FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D01AA08; WHO ATC D01BA01

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

9registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Griseofulvin, Microsize in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Griseofulvin, Microsize with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clinical, Dermoscopic, and Mycological Evaluations of Resistant Dermatophytosis

    NCT07796854 · start 2026-10-01

    Registered record
    Registry ID
    NCT07796854
    Conditions
    Fungal Skin Infection; Tinea Corporis
    Interventions
    Direct microscopic KOH examination; Culture:; Antifungal susceptibility testing:; Conventional PCR:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2027-08-20
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Skin Infection; Tinea Corporis
    InterventionDirect microscopic KOH examination; Culture:; Antifungal susceptibility testing:; Conventional PCR:
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Clinical, Dermoscopic, and Mycological Characteristics of Tinea Capitis in Children

    NCT07802600 · start 2026-09-20

    Registered record
    Registry ID
    NCT07802600
    Conditions
    Fungal Infection by Site; Tinea Capitis
    Interventions
    Dermoscopic examination: the findings are divided into pathognomic and non-specific signs; Direct Microscopy (KOH) examination; Fungal culture:; Antifungal sensitivity:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-09-20
    Completion
    2027-08-20
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Infection by Site; Tinea Capitis
    InterventionDermoscopic examination: the findings are divided into pathognomic and non-specific signs; Direct Microscopy (KOH) examination; Fungal culture:; Antifungal sensitivity:
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions

    NCT04318535 · start 2020-01-13

    Registered record
    Registry ID
    NCT04318535
    Conditions
    Antifungal Agents
    Interventions
    Griseofulvin 500 mg; Griseofulvin 250 mg; Reference Griseofulvin 500 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-13
    Completion
    2020-02-06
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntifungal Agents
    InterventionGriseofulvin 500 mg; Griseofulvin 250 mg; Reference Griseofulvin 500 mg
    PhasePhase 1
    Registry statusCompleted

  • Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH

    NCT01518166 · start 2006-05

    Registered record
    Registry ID
    NCT01518166
    Conditions
    Diabetes; Healthy
    Interventions
    liraglutide; placebo; atorvastatin; lisinopril; griseofulvin; digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-05
    Completion
    2007-04
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Healthy
    Interventionliraglutide; placebo; atorvastatin; lisinopril +2 more
    PhasePhase 1
    Registry statusCompleted

  • A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Non-fasting Conditions

    NCT00863863 · start 2006-01

    Registered record
    Registry ID
    NCT00863863
    Conditions
    Healthy
    Interventions
    Griseofulvin 125 mg/5 mL Suspension, single dose; Grifulvin V® 125 mg/5 mL Suspension, single dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-01
    Completion
    2006-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionGriseofulvin 125 mg/5 mL Suspension, single dose; Grifulvin V® 125 mg/5 mL Suspension, single dose
    PhasePhase 1
    Registry statusCompleted

  • A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions

    NCT00864071 · start 2005-11

    Registered record
    Registry ID
    NCT00864071
    Conditions
    Healthy
    Interventions
    Griseofulvin 125 mg/5 mL Suspension, single dose; Grifulvin V® 125 mg/5 mL Suspension, single dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-11
    Completion
    2005-11
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionGriseofulvin 125 mg/5 mL Suspension, single dose; Grifulvin V® 125 mg/5 mL Suspension, single dose
    PhasePhase 1
    Registry statusCompleted

  • Selenium Sulfide, Ketoconazole and Ciclopirox Shampoo as Additional Treatments for Tinea Capitis (Scalp Ringworm)

    NCT00127868 · start 2005-03

    Registered record
    Registry ID
    NCT00127868
    Conditions
    Tinea Capitis
    Interventions
    oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-03
    Completion
    2008-04
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTinea Capitis
    Interventionoral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo
    PhaseNot applicable
    Registry statusCompleted

  • Terbinafine Compared to Griseofulvin in Children With Tinea Capitis

    NCT00117754 · start 2004-07

    Registered record
    Registry ID
    NCT00117754
    Conditions
    Tinea Capitis
    Interventions
    Terbinafine hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-07
    Completion
    2006-04
    Enrolment
    720

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTinea Capitis
    InterventionTerbinafine hydrochloride
    PhasePhase 3
    Registry statusCompleted

  • Terbinafine Compared to Griseofulvin in Children With Tinea Capitis

    NCT00117767 · start 2004-06

    Registered record
    Registry ID
    NCT00117767
    Conditions
    Tinea Capitis
    Interventions
    Terbinafine hydrochloride (HCl); Griseofulvin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-06
    Completion
    Not recorded
    Enrolment
    720

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTinea Capitis
    InterventionTerbinafine hydrochloride (HCl); Griseofulvin
    PhasePhase 3
    Registry statusCompleted